Xeris Biopharma Holdings, Inc. XERS Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s debt issuance cost amortization?
- Xeris Biopharma Holdings, Inc. (XERS) reported debt issuance cost amortization of $889K in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s debt issuance cost amortization changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s debt issuance cost amortization increased by 5.3% year-over-year, from $844K to $889K.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s debt issuance cost amortization?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s debt issuance cost amortization has grown at a 36.2% compound annual growth rate (CAGR), from $961K to $3.31M.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).